Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating'Market Watch • 11/04/24
Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025Reuters • 11/04/24
HIMS Q3 Estimates Unchanged Before Earnings: How to Play the Stock?Zacks Investment Research • 11/01/24
How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss GoalsBusiness Wire • 10/29/24
Hims & Hers Health Tops Growth 50 List As FDA OKs Cheaper Weight-Loss DrugInvestors Business Daily • 10/21/24
Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk.Investors Business Daily • 10/16/24
Hims & Hers Stock Jumps as FDA Reconsiders Restrictions on Copycat Weight-Loss DrugsInvestopedia • 10/14/24
Hims & Hers to Announce Third Quarter 2024 Financial Results on November 4, 2024Business Wire • 10/14/24
Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity DrugInvestors Business Daily • 10/14/24
Hims & Hers Health (HIMS) Soars 10.1%: Is Further Upside Left in the Stock?Zacks Investment Research • 10/08/24